Rebecca Newberry APRN MS CDE

Similar documents
Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Diabetes Medication Updates Erica Bukovich, PharmD, BC-ADM, CDE September 20, 2018

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

DM Fundamentals Class 4 Meds for Type 2

Diabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

RPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics

Initiating Injectable Therapy in Type 2 Diabetes

DM Fundamentals Class 4 Meds for Type 2

Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018

DIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Pharmacologic Agents for Treatment of Type 2 Diabetes

What s New in Diabetes Treatment. Disclosures

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

What s New in Diabetes Medications. Jena Torpin, PharmD

DIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013

Individualizing Care for Patients with Type 2 Diabetes

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

What s New on the Horizon: Diabetes Medication Update

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

Copyright 2003 How long does it take metformin to lower blood sugar. All rights reserved.

Changing Diabetes: The time is now!

Clinical Practice Guidelines

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

Innovative, Unusual Therapies for DM-2: Insulin U-500, Bromocriptine, Colesevelam, and SGLT2 inhibitors. April 3 rd, 2014

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

I. General Considerations

The Death of Sulfonylureas? A Review of New Diabetes Medications

What s New in Type 2 Diabetes? 2018 Diabetes Updates

New Therapies for Diabetes Management: Hope or Headache?

The Many Faces of T2DM in Long-term Care Facilities

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

New Therapies for Diabetes

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Diabetes Medications: Oral Anti-Hyperglycemic Medications

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

Diabetes: Inpatient Glucose control

SGLT2 Inhibitors

Diabetes Management: A diagnostic perspective

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Metabolic Syndrome: What s so big about BIG?

Physician Drug Reference Chart for Diabetes Antidiabetic Medications

Type 2 Diabetes Mellitus hypoglycaemic agents

Comprehensive Diabetes Treatment

Diabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services

OBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting

SGLT2 Inhibitors

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

Insulin Initiation and Intensification. Disclosure. Objectives

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Diabetes Mellitus II CPG

Northern California Chapter ACP Update In Medicine I

The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP

Diabetes, Drugs and Dangerous Discrepancies. Sally Bodenhamer, OD, OT/L, CDE

Multiple Factors Should Be Considered When Setting a Glycemic Goal

Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Adlyxin. (lixisenatide) New Product Slideshow

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Oral and Injectable Non-insulin Antihyperglycemic Agents

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

How they work and when to take them. Diabetes Medications

Pharmacology. Kacy Aderhold, MSN, APRN-CNS, CMSRN

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Newer Drugs in the Management of Type 2 Diabetes Mellitus

SGLT2 Inhibitors

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!

Table 1. Antihyperglycemic agents for use in type 2 diabetes

What s New in Type 2 Diabetes? 2018 Diabetes Updates

Non-Insulin Diabetes Medications Summary

Diabetes School October 2016

Chief of Endocrinology East Orange General Hospital

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

I have no financial incentives or conflicts of interest to disclose for this presentation.

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

Drugs used in Diabetes. Dr Andrew Smith

Endo 2 SLO Practice (online) Page 1 of 7

CASE A2 Managing Between-meal Hypoglycemia

Implementing Hospital Policies & Protocols

6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE

Rhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain

Transcription:

Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board Astrazeneca, Boehringer-Ingelheim, Janssen, Novo Nordisk, Sanofi, Valeritas Explain diabetes medications to patients Apply medication information to various clinical settings, including surgical setting Identify various technologies used in diabetes management Physiology and Pathophysiology Basic Diabetes education process/program Use appropriate language Basis for understanding diabetes management Lifestyle - diet, activity, monitoring Medication adherence Follow up 1

Treating Physiology Medication Choices Addressing the various pathologies of diabetes leads to Combination Therapy Continue metformin when possible Do not mix drugs of same class/similar action Watch for side effects Be aware of cost issues Fab Four Metformin, Actos, GLP1, SGLT2 Patient centered approach should be used to guide choice of pharmaceutical agents Efficacy Hypoglycemia risk History of CV disease Impact on weight Potential side effects Renal effects Delivery method Cost Patient preferences Metformin Metformin Action Decreases hepatic glucose output Use First line med at diagnosis, continue Benefits No hypo or weight gain, approved for peds, 10 yrs+ Cost generic inexpensive. XR may be more Side effects nausea, bloating, gas, diarrhea, B12 deficiency with long term use To minimize GI effects, use XR, take with meals Considerations Obtain GFR before starting If <30, do not use If 30-45, use half maximum dose, evaluate risk/benefit For Dye study Stop on day of study, restart in 48 hours if renal function stable Risk for lactic acidosis Sulfonylureas Meglitinides Action Stimulates sustained insulin release from pancreas Use After metformin Benefits effective, available Cost - Low cost generic Side effects hypoglycemia and weight gain Considerations Must be taken with meal, timing very important, QD or BID Action Stimulates rapid insulin release from pancreas Use Before meals to affect post meal blood sugars Benefits Short duration of action, less hypoglycemia than long acting sfu Cost generic/branded Side effects hypoglycemia, weight gain 2

Thiazolidinediones (TZD) TZDs Action- Increases insulin sensitivity Use Black Box warning may cause or worsen CHF. Monitor for edema and weight gain. Increased risk for peripheral fractures, bladder cancer Benefits- Only med to work at receptor site Cost generic/low cost Side effects weight gain, edema Considerations takes 3 months for full effect, long duration of action when stopped GLP-1 Receptor Agonists GLP-1 Actions Increases insulin release with food, slows gastric emptying, promotes satiety, suppresses glucagon Use Black box warning Thyroid C-cell tumor Second line choice Benefits Decreased hypoglycemia, may help with weight loss, Victoza found to decrease risk of CV death, HA, stroke Cost Brand name only Side effects nausea, vomiting, weight loss, injection site reactions. Report signs of acute pancreatitis: severe abdominal pain, vomiting. Stop med Considerations Daily or weekly formulations. May decrease need for insulin, sulfonylureas DPP-IV Inhibitors DPP-IVs Actions- Prolongs action of gut hormones, increases insulin secretion, delays gastric emptying Uses Second line after metformin. Benefits No hypoglycemia or weight gain, few side effects Cost Branded only Side effects headache, flu-like symptoms Considerations- may decrease dose if renal function decreased (not Tradjenta). Can cause joint pain, report signs of pancreatitis. Some may increase risk of heart failure. 3

SGLT2 Inhibitors SGLT2s Action Decrease glucose reabsorption in the kidney Uses Second line, may be limitations to use if GFR decreased Benefits no hypoglycemia, may help with weight loss Cost Branded only Side Effects Genital mycotic infection, UTI, increased urination, hypotension, ketoacidosis Considerations Decrease risk of death from CV disease. Invokana may increase risk of amputation in high risk patients, don t use Farxiga in patients with bladder cancer. Need to increase fluid intake. Practice good genital hygiene Alpha Glucosidase Inhibitors Amylin Analog- Symlin Action Delays carbohydrate absorption Use Not commonly used Benefits Oral med, works with diet Cost Generic Side effects GI upset, gas, abdominal cramping Considerations Start low dose. Caution with liver/kidney problems. Hypoglycemia risk Actions Suppresses glucagon, slows gastric emptying, promotes satiety Use Type 1 or Type 2 diabetes, on insulin. Black box warning severe hypoglycemic risk, decrease insulin dose when starting Benefits Decreases insulin requirments, may help with weight loss Cost Branded only Symlin Dopamine Receptor Agonist Side Effects nausea, weight loss Considerations needs to be injected with insulin before meals Action Resets circadian rhythm, helping to decrease insulin resistance Use Not first or second line Benefits May decrease other medication doses Cost Branded (Quick Release bromocriptine) Side Effects Nausea, headache, fatigue, hypotension, dizziness 4

Cycloset Bile Acid Sequestrants Considerations Take 6 tabs within 2 hour of wakening Action Decreases cholesterol and blood glucose Use Not first or second line Benefits Dual action, lowers LDL 15-30% Cost Brand name Side effects GI issues, diarrhea. Can decrease absorption of certain meds, soluble vitamins Welchol Insulin Considerations Do not use if history of bowel obstruction, triglycerides over 500, or pancreatitis. Action Replaces insulin to take glucose into cell for metabolism Uses All types of diabetes, used first or second line. Usually effective in bringing blood sugars down. Benefits Works quickly, dosing can be individualized, many choices of formulations Insulin Technology in Diabetes Management Cost Are generics and biosimilars, but still not inexpensive. Many new formulations are Brand name. Side effects Hypoglycemia, weight gain Considerations Education is vital for patients to use appropriately. Injection technique, timing of dosing, etc. Need to be aware of different formulations, onset of action, duration. Meters for glucose testing Continuous Sensors Insulin Delivery Systems 5

Technology in Diabetes Management Technology in Diabetes Management Rapid evolution in recent years Patient driven Issues related to security, safety, privacy Clinicians need to be knowledgeable Systems set up to use newest technology Continuous Glucose Sensors Measures intracellular fluid glucose levels, correlates to blood glucose Consists of sensor, transmitter, display Sensors changed every 7-10 days Dexcom, Medtronic Enlite, Freestyle Flash Insulin Delivery Systems V-Go mechanical delivery device, takes the place of insulin injections. Device filled with insulin, changed every 24 hours. Set basal dosing, not able to be changed. Bolus dosing done per clicks on the device 6

Insulin Delivery Systems Insulin Pumps Omni Pod Tubeless, insulin delivered by pod attached to body, controlled by separate PDM (Personal Data Manager). Tandem uses tube, touchscreen display and adjustment. Updates done by computer. Medtronic 670-G system Pump and Sensor are connected, can be used in Automatic mode to deliver basal insulin automatically, based on blood sugar reading. Still need to bolus mealtime insulin. Use of Pump in Hospital Policies vary by institution Need to assure patient has ability to handle Continuous insulin dosing, using pump If possible, keep pump on patient May need to stop for safety Staff need to understand basic pump functions basal rates, bolus ratios etc 7

Peri-Operative Considerations Guidelines Goals Reduce overall morbidity/mortality Avoid severe hyper or hypo glycemia Maintain electrolyte/fluid balance Prevent ketoacidosis Vary per institution Surgery Research and Practice 2015:284063 Guidelines for Perioperative Management of the Diabetic Patient Individualized based on medical history, glycemic control, procedure planned Pre Op Pre Op Oral meds stop day of surgery, resume when eating/drinking normally Injectables stop day of surgery, resume when appropriate Basal (Long acting) insulin Lantus, Levemir, Basaglar, Tresiba, Toujeo, NPH Partial dose day before/day of surgery, Bolus (rapid or mealtime) insulin Novolog, Humalog, Apidra, Regular Stop day of surgery Use as correction (sliding scale) when BS tested Resume appropriate dose when eating normally Cancelling Surgery Intra Op No evidence based guideline No surgery on patients in compromised metabolic state (DKA) 400-500 mg/dl Variables patient, procedure, surgeon BG range 140-170 lowest risk of adverse outcomes Monitor frequently IV insulin or Insulin infusion IV insulin active for 1 hour, serum half life of 7 minutes 8

Post Op Nursing Approach to Patient with Diabetes Variables affect glycemic control Physiologic stress, NPO status Diligent BG testing Use correction (sliding scale) based on BS results Resume basal insulin asap Resume orals/injectables as tolerated Non judgmental approach NOT a lifestyle disease understand physiology Assess issues regarding management Barriers to non adherence Treat with compassion Educate Use resources NEVER give up on a patient Nursing Approach to Patient with Diabetes References Educate yourself Diabetes field is rapidly changing Be open to new information Patient often great source of information Diabetes Resources ADA and ADA Pro Diabetes in Control Methodist Center for Diabetes and Nutritional Health 8111 Dodge Street, Suite 332 402-354-8797 Standards Of Medical Care in Diabetes. Diabetes Care 41:Supplement 1. American Diabetes Association, January 2018. Guideline for Perioperative Management of the Diabetic Patient. Sudhakaran, S, et al, Surgery Research and Practice 2015:294063, May 19, 2015. Questions? 9